



ORIGINAL

The Role of *HCN4* Variants in Human Systolic Heart Failure and Protein Interaction Network

El Papel de las Variantes del *HCN4* en la Insuficiencia Cardíaca Sistólica Humana y Red de Interacción de Proteína

Rasmaya Niruri^{1,2}  , Zullies Ikawati¹  , Agung Endro Nugroho¹  , Habibie Arifianto³  

¹Faculty of Pharmacy, Universitas Gadjah Mada. Yogyakarta, Indonesia.

²Département of Pharmacy, Faculty Mathematics and Sciences. Universitas Sebelas Maret, Surakarta, Indonesia.

³Faculty of Medicine, Universitas Sebelas Maret. Surakarta, Indonesia.

Cite as: Niruri R, Ikawati Z, Nugroho AE, Arifianto H. The Role of *HCN4* Variants in Human Systolic Heart Failure and Protein Interaction Network. Salud, Ciencia y Tecnología. 2025; 5:1101. <https://doi.org/10.56294/saludcyt20251101>

Submitted: 18-04-2024

Revised: 01-08-2024

Accepted: 03-12-2024

Published: 01-01-2025

Editor: Prof. Dr. William Castillo-González 

Corresponding author: Rasmaya Niruri 

ABSTRACT

Introduction: an elevated heart rate (HR) results in adverse outcomes in human systolic heart failure with a sinus rhythm. Genetic variants may alter *HCN4* interactions with regulatory proteins and increase HR. This study aimed to generate a protein interaction network (PIN) associated with elevated HR and to determine *HCN4* gene variants (718G>A, 1571G>A, and 2648C>G) in patients with systolic heart failure, sinus rhythm, and elevated heart.

Method: STRING protein database was used to generate a PIN. Laboratory exploration was performed to identify *HCN4* gene variants in patients with systolic heart failure using PCR and DNA sequencing.

Results: PIN revealed eight nodes and 13 edges. STRING functional enrichment showed the essential proteins (ADRB1 and HCN channels) involved in HR regulation. GNAS and ADCY1 contributed to the regulation process. *HCN4* gene variants (718G>A, 1571G>A, and 2648C>G) alter the properties of HCN4 channel. STRING scores of protein-protein interactions that involved HCN4, ADRB1, GNAS, and ADCY1 were high (in the range of 0,879-0,979). The three gene variants were evaluated in 49 study participants with HR \geq 70 bpm after 10 mg bisoprolol therapy. However, only 718G>A was identified in three of 49 patients.

Conclusion: PIN revealed that the three essential proteins associated with HCN4 channels in elevating HR were ADRB1, GNAS, and ADCY1. Only *HCN4* 718G>A was found in three out of 49 patients with systolic heart failure, sinus rhythm, and increased HR, according to a laboratory investigation on *HCN4* gene variants.

Keywords: Systolic Heart Failure; Heart Rate; *HCN4*.

RESUMEN

Introducción: una frecuencia cardíaca (FC) elevada produce resultados adversos en insuficiencia cardíaca sistólica humana con ritmo sinusal. Las variantes genéticas pueden alterar las interacciones del *HCN4* con las proteínas reguladoras y aumentar la FC. Este estudio tuvo como objetivo crear una red de interacción de proteínas relacionadas con el aumento de la FC y determinar las variantes del gen *HCN4* (718G>A, 1571G>A y 2648C>G) en pacientes con insuficiencia cardíaca sistólica, ritmo sinusal y corazón elevado.

Método: se utilizó la base de datos de STRING proteínas para describir la red de interacción de proteínas. Se aplicó exploración de laboratorio (con PCR y secuenciación de ADN) para identificar la variante del gen *HCN4* en humanos.

Resultados: la PIN reveló ocho nodos y 13 bordes. STRING reveló proteínas importantes (ADRB1 y HCN) involucradas en la regulación de la frecuencia cardíaca. Las variantes del gen *HCN4* (718G>A, 1571G>A y

2648C>G) alteran las propiedades del canal HCN4. Las puntuaciones STRING de interacción proteína-proteína para HCN4, ADRB1, GNAS y ADCY1 mostraron valores altos (que oscilan entre 0,879 y 0,979). Los tres genes fueron evaluados en 49 pacientes con FC ≥ 70 lpm después de un tratamiento con 10 mg de bisoprolol. Sin embargo, sólo se identificó 718G>A en tres de 49 pacientes.

Conclusiones: PIN reveló tres proteínas importantes (ADRB1, GNAS, and ADCY1) que interactúan con HCN4. Basado en investigación de laboratorio, sólo se encontró HCN4 718G>A en tres de 49 pacientes diagnosticados con insuficiencia cardíaca sistólica, ritmo sinusal y FC elevada.

Palabras clave: Insuficiencia Cardíaca Sistólica; Frecuencia Cardíaca; HCN4.

INTRODUCTION

Systolic heart failure had a high distribution and mortality rate compared with diastolic heart failure.⁽¹⁾ A resting heart rate (HR) of ≥ 70 beats per minute (bpm) in systolic heart failure subjects with sinus rhythm significantly enhanced the risk of death.⁽²⁾ HR reduction demonstrated beneficial outcomes for decreasing mortality rates.⁽³⁾ Bisoprolol, a beta-1 adrenergic receptor (ADRB1) blocker, was recommended for rate lowering in heart failure. Bisoprolol protects cardiac against excessive catecholamine stimulation, continuous beta-adrenergic signaling, and cardiotoxic neurohormonal systems.^(4,5) In clinical practice, achieving a target HR using ADRB1 blockers was difficult.⁽⁶⁾

Genetic variations play a role in regulating resting HR and cardiovascular diseases.⁽⁷⁾ Hyperpolarization-activated cyclic nucleotide-gated 4 (HCN4), the primary hyperpolarization-activated cyclic nucleotide-gated (HCN) channel, is found in the sinoatrial (SA) node in humans. HCN4 plays a crucial role in pacemaker current and autonomic regulation of HR. HCN4 prompts to initiate heart rhythm.^(8,9) Mutations in the *HCN4* gene are reported to be associated with tachycardia.^(10,11,12,13) The three identified *HCN4* variants associated with elevated HR/tachycardia were *HCN4* c.718G>A(p.Val240Met), c.1571G>A(p.Arg524Gln), and c.2648C>G (p.Pro883Arg).^(10,11,12) However, the effect of *HCN4* gene variants on HR varies.^(10,13,14,15) Regulatory proteins that are interacted/complexed with HCN channel define different functions of the channel.⁽⁸⁾ Therefore, this study aimed to create a protein interaction network (PIN) associated with elevated HR and determine the gene variants in patients with systolic heart failure, sinus rhythm, and elevated HR. This research provided valuable insights into the genetic factors and proteins that increase HR and expanded the view of controlling the HR mechanism associated with HCN4. These findings will expand systolic heart failure's diagnostic and treatment options.

METHOD

Protein interaction network

The STRING database was used to generate a PIN and to analyze functional protein pathways. The PPI in STRING networks was performed according to the procedure provided by the STRING consortium 2023.⁽¹⁶⁾ STRING scores of 0,700 and 0,900 indicated high confidence and the highest interaction, respectively.⁽¹⁷⁾

HCN4 gene variants identification in human systolic heart failure with sinus rhythm and elevated HR

This study was approved by the ethics committee of Universitas Sebelas Maret and conducted at Sebelas Maret Hospital, Surakarta, Indonesia. The inclusion criteria for this study were adult patients (≥ 18 years old) with systolic heart failure, sinus rhythm, and elevated HR (HR ≥ 70 bpm) who had received 10 mg once daily of bisoprolol. The exclusion criteria were unwillingness to sign an informed consent form. Laboratory exploration was applied to identify the *HCN4* gene variant in the patients using polymerase chain reaction (PCR) and deoxyribonucleic acid (DNA) sequencing. DNA isolation and amplification were performed according to the procedures provided with the GeneJET Genomic DNA Purification Kit (Thermo Fisher Scientific Inc.) and GoTag Geen (Promega). *HCN4* variants (718G>A, 1571G>A, and 2648C>G) were amplified with PCR primers (table 1). The sequencing result aligned with the NCBI reference sequence (NG_009063,1) for determining the gene variants.⁽¹⁸⁾

SNP (exon)	Primers
718G>A (1 st) ⁽¹⁰⁾	(F):5'AGCAGCCCTCGGTGGACA'3; (R):5'ACCCACAGGATCATCGCTGT'3; 277 bp. ⁽¹⁹⁾
1571G>A (4 th) ⁽¹¹⁾	(F): 5' TTCCCTCTCATCCACTGTCCC3'; (R):5' GACCAATGTGCGGGTGTCTCC 3'; 295 bp. ⁽¹¹⁾
2648C>G (8 th) ⁽¹²⁾	(F): 5' GATCCCTTCTGCGCTGGGCT; (R):TGAGCAGGGGAGAGTCCGGAG; 285 bp. ⁽¹⁹⁾

Note: bp=base pair; F= forward primer; R=reverse primer; SNP = single nucleotide polymorphism.

RESULT

The PIN revealed a STRING average local clustering coefficient of 0,779 (figure 1). Protein-protein interaction (PPI) data was presented on node-node interaction. Most of the PPI scores were around the highest confidence interaction. However, it was not applied to the protein interaction with guanine nucleotide-binding protein G(t) subunit alpha-3 (GNAT3), in which all the scores were lower than 0,700. Functional enrichment of the proteins (HCN, ADRB1, Guanine nucleotide subunit alpha (GNAS) and adenylyl cyclase type 1 (ADCY1)) network showed clusters of biological processes and molecular functions with low false discovery rates. Proteins involved in HR regulation were ADRB1 and four types of HCN channels. GNAS and ADCY1 contributed to the regulation process. ⁽¹⁶⁾ *HCN4* variants (c.718G>A (p.Val240Met), c.1571G>A (p.Arg524Gln), and c.2648C>G (p.Pro883Arg)) alter the properties of HCN4 channel^(10,11,12) we identified a mutation (p.V240M)




Figure 1. HCN4 channel and protein-protein interaction network

HCN4 gene at 718, 1571, and 2648 positions were evaluated in 49 patients (table 2, figure 2). Three subjects carried 718GA, and the rest had a wild type (WT) variant (718GG), which revealed double peaks and a single peak on the sequencing chromatogram, respectively (figure 2(A)). The WT gene variants (*HCN4* 1571GG and 2648CC) were identified in all patients (figure 2(B and C)).

Table 2. *HCN4* gene variant in human systolic heart failure with sinus rhythm and elevated HR after receiving 10 mg bisoprolol

Subjects *	<i>HCN4</i> 718			<i>HCN4</i> 1571			<i>HCN4</i> 2648		
(N _{total} =49)	G	GA	AA	GG	GA	AA	CC	CG	GG
N	46	3	0	49	0	0	49	0	0
%	94 %	6 %	0 %	100 %	0 %	0 %	100 %	0 %	0 %

Note: (*) = All 49 patients were not diagnosed with anemia, fever, infectious disease, thyroid disorder, or decompensated heart failure; elevated HR=HR ≥ 70 bpm




Figure 2. Sequencing chromatogram of *HCN4* variants: (A) 718GG (top) and 718GA (bottom); (B) 1571GG; (C) 2648CC

DISCUSSION

The PIN revealed the association of *HCN* channels, *ADRB1*, *GNAS*, and *ADCY1* (figure 2). *HCN* channels are crucial in generating cardiac automaticity.⁽⁸⁾ *HCN4* is predominantly expressed in the SA node region.^(20,21,22) Adenylyl cyclase (*ADCY*) is an enzyme that catalyzes cAMP production in the beta-adrenergic signaling pathway. *ADCY1* is the predominant isoform in the SA node.^(21,22) The synchronous work between *HCN4* and *ADCY1* is essential in the SA node after beta-adrenergic stimulation. *ADCY1* contributes to the higher level of cAMP in the SA node. The role of cAMP is crucial in regulating cardiac contractility and chronotherapy. The gene variants affect *HCN4* channel properties and protein interactions.^(11,21,22) *HCN4* 1571 variant alters the cAMP binding to the *HCN4* channel.⁽¹¹⁾ The nucleotide change on *HCN4* 1571G>A (p.Arg524Gln) enhances cAMP sensitivity. The location of Arg524Gln is in the C-linkers (a part connecting cyclic nucleotide-binding domain (CNBD) to the S6 transmembrane domain) of the *HCN4* channel, which is the binding site of cAMP for channel activation. Based on HEK293 cell and an animal study, as compared to the wildtype (WT) channel, the mutation (p.Arg524Gln) was more sensitive to cAMP, which led to more sensitivity to adrenergic stimulation and a faster pacemaker rate. Ivabradine blocked both the mutant and WT *HCN4* channel carriers similarly.^(11,21,22)

HCN4 is crucial in regulating SA node potential (figure 1).⁽⁸⁾ *HCN4* expression affects pacemaker current (*I_f*) and activity. *HCN4* 2648C>G (p.Pro883Arg) and 718G>A (p.Val240Met) alter the *HCN4* current.⁽¹¹⁾ The location of p.Pro883Arg is in the distal C-terminus of *HCN4* comprised C-linker, which is linked to the transmembrane region with the CNBD. Based on functional analyses, the replacement of proline by arginine (p.Pro883Arg) altered the channel's current to a more positive potential, and the channel property to a more depolarized potential.^(12,23) Meanwhile, the location of p.Val240Met is in *HCN*-domain (*HCND*) at the N terminus.⁽¹⁰⁾ *HCND* interacts with the channel voltage-sensing domain (VSDs) and cyclic nucleotide-binding domain (CNBD) of *HCN* channel gating.⁽²²⁾ The couple of *HCND* and VSD are crucial for *HCN4* channel expression. The mutant channel increased the channel current and beating rate.⁽¹⁰⁾

All 49 patients carried the wild type of *HCN4* 1571 and 2648 gene. *HCN4* 1571G>A and 2648C>G were not identified in this study participants (table 2, figure 2). Heterozygous 1571GA was detected in five of ten Italian patients with IST or sinus tachycardia.⁽¹¹⁾ Heterozygous 2648CG is a genetic factor associated with tachycardia-induced cardiomyopathy in German patients with atrial fibrillation.⁽¹²⁾ Both of these variants occur infrequently

in a population. Based on NCBI data (NM_005477.3(*HCN4*):c.1571G>A(p.Arg524Gln)), the frequencies are 0,0040 %, 0,000 %, and 0,000 % in 26588 European, 2918 African, and 112 Asian populations.^(24,25) Meanwhile, frequencies of the variant (NM_005477.3(*HCN4*):c.2648C>G(p.Pro883Arg)) are 1,0840 %, 0,3140 %, and 0,000 % in 35526 European, 3574 African, and 168 Asian populations.^(23,26)

Based on the gene variant exploration in this study, only *HCN4* 718G>A was identified in three patients (table 2, figure 2). The mutant allele frequency was rare (0,0004 %) in South Asian population. Meanwhile, the variant was identified in nine of 16 Spanish patients. *HCN4* 718G>A was responsible for inappropriate sinus tachycardia (IST) in Spanish patients.⁽¹⁰⁾ Anemia, fever, hyperthyroidism, and decompensated heart failure increase HR.⁽⁴⁾ Increased body temperature is associated with HR modulation.⁽²⁷⁾ Anemia and hyperthyroidism enhance sympathetic activity, increasing HR.^(28,29) None of these disorders were identified in this study participants (table 2). Heterozygous *HCN4* 718GA enhanced the pacemaker beating rate⁽¹⁰⁾, thus explaining the elevated HR of the carriers (table 2). Ivabradine (*HCN* channel inhibitor) treatment with or without bisoprolol was reported to reverse the IST of the *HCN4* 718G>A carriers with or without a low ejection fraction.⁽¹⁰⁾ Therefore, a combination with ivabradine was recommended for 718G>A carriers not controlled with bisoprolol alone.

CONCLUSION

PIN revealed that the three important proteins associated with *HCN4* channels in elevating HR were *ADRB1*, *GNAS*, and *ADCY1*. According to the laboratory investigation of *HCN4* gene variants, only *HCN4* 718G>A was found in three of 49 patients with systolic heart failure, sinus rhythm, and increased HR.

REFERENCES

1. Irnizarifka, Arifianto H. The Comprehensive Registry and Research on Heart Failure (CORE-HF): 2 years report from single-center Indonesian heart failure clinic registry. *Acta Cardiologia Indonesiana*. 2021;7(2):10. <https://doi.org/10.22146/jaci.v7i2.2266>
2. Kurgansky KE, Schubert P, Parker R, Djousse L, Riebman JB, Gagnon DR, et al. Association of pulse rate with outcomes in heart failure with reduced ejection fraction: a retrospective cohort study. *BMC Cardiovasc Disord*. 2020;20(1):92. <https://doi.org/10.1186/s12872-020-01384-6>.
3. Tsai M-L, Lin S-I, Kao Y-C, Lin H-C, Lin M-S, Peng J-R, et al. Optimal Heart Rate Control Improves Long-Term Prognosis of Decompensated Heart Failure with Reduced Ejection Fraction. *Medicina (Kaunas)*. 2023;59(2). <https://doi.org/10.3390/medicina59020348>.
4. Hasanah DY, Zulkarnain E, Arifianto H, Sasmaya H, Suciadi LP, Dewi PP, et al. Pedoman Tatalaksana Gagal Jantung. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. 2023. <https://www.inaheart.org/storage/guideline/d4c92daca60a4c18c6d846209646c24e.pdf>
5. Masarone D, Martucci ML, Errigo V, Pacileo G. The use of B-blockers in heart failure with reduced ejection fraction. *J Cardiovasc Dev Dis*. 2021;8(9):101. <https://doi.org/10.3390/jcdd8090101>
6. Waranugraha Y, Rizal A, Tjahjono CT, Vilado IY, David NI, Abudan F, et al. A Systematic Review and Meta-Analysis of Randomised Controlled Trials Assessing Clinical and Haemodynamic Outcomes of Ivabradine in Heart Failure With Reduced Ejection Fraction Patients. *Heart Lung Circ*. 2024;33(7):962-974. <https://doi.org/10.1016/j.hlc.2023.09.005>
7. van de Vegte YJ, Eppinga RN, van der Ende MY, Hagemeyer YP, Mahendran Y, Salfati E, et al. Genetic insights into resting heart rate and its role in cardiovascular disease. *Nat Commun* 2023;14(1):4646. <https://doi.org/10.1038/s41467-023-39521-2>.
8. Depuydt A-S, Peigneur S, Tytgat J. Review: *HCN* Channels in the Heart. *Curr Cardiol Rev* 2022;18(4):e040222200836. <https://doi.org/10.2174/1573403X18666220204142436>.
9. Hennis K, Piantoni C, Biel M, Fenske S, Wahl-Schott C. Pacemaker Channels and the Chronotropic Response in Health and Disease. *Circ Res*. 2024;134(10):1348-78. <https://doi.org/10.1161/CIRCRESAHA.123.323250>.
10. Cámara-Checa A, Perin F, Rubio-Alarcón M, Dago M, Crespo-García T, Rapún J, et al. A gain-of-function *HCN4* mutant in the *HCN* domain is responsible for inappropriate sinus tachycardia in a Spanish family. *Proc Natl Acad Sci U S A*. 2023;120(49):e2305135120. <https://doi.org/10.1073/pnas.2305135120>.
11. Baruscotti M, Bucchi A, Milanese R, Paina M, Barbuti A, Gneccchi-Ruscione T, et al. A gain-of-function

mutation in the cardiac pacemaker HCN4 channel increasing cAMP sensitivity is associated with familial Inappropriate Sinus Tachycardia. *Eur Heart J*. 2017;38(4):280-8. <https://doi.org/10.1093/eurheartj/ehv582>.

12. Weigl I, Geschwill P, Reiss M, Bruehl C, Draguhn A, Koenen M, et al. The C-terminal HCN4 variant P883R alters channel properties and acts as genetic modifier of atrial fibrillation and structural heart disease. *Biochem Biophys Res Commun*. 2019;519(1):141-7. <https://doi.org/10.1016/j.bbrc.2019.08.150>.

13. Nakano Y. Genome and atrial fibrillation. *J Arrhythmia*. 2023;39(3):3039. <https://doi.org/10.1002/joa3.12847>.

14. Verkerk AO, Wilders R. The Action Potential Clamp Technique as a Tool for Risk Stratification of Sinus Bradycardia Due to Loss-of-Function Mutations in HCN4: An In Silico Exploration Based on In Vitro and In Vivo Data. *Biomedicines*. 2023;11(9):2447. <https://doi.org/10.3390/biomedicines11092447>

15. Vedantham V, Scheinman MM. Familial inappropriate sinus tachycardia: a new chapter in the story of HCN4 channelopathies. *Eur Heart J*. 2017;38(4):289-91. <https://doi.org/10.1093/eurheartj/ehv635>.

16. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res*. 2023;51(D1):D638-646. <https://doi.org/10.1093/nar/gkac1000>

17. Bozhilova L V, Whitmore A V, Wray J, Reinert G, Deane CM. Measuring rank robustness in scored protein interaction networks. *BMC Bioinformatics*. 2019;20(1):446. <https://doi.org/10.1186/s12859-019-3036-6>.

18. NCBI. Homo sapiens HCN4: RefSeqGene on chromosome 15. NCBI-Natl Cent Biotechnol. 1993. https://www.ncbi.nlm.nih.gov/nucore/NG_009063.1%0A%0A.

19. Ueda K, Hirano Y, Higashiuesato Y, Aizawa Y, Hayashi T, Inagaki N, et al. Role of HCN4 channel in preventing ventricular arrhythmia. *J Hum Genet* 2009;54(2):115-121. <https://doi.org/10.1038/jhg.2008.16>

20. Niruri R, Ikawati Z, Nugroho AE, Arifianto H. Beta-Blocker in Heart Rate Control and Cardio Protection: The Role of ADRB1 Variants and HCN4 Regulation-A Systematic Review. *Indonesian Journal of Pharmacy*. 2024;35(3):375-391. <https://doi.org/10.22146/ijp.8310>

21. Ren L, Thai PN, Gopireddy RR, Timofeyev V, Ledford HA, Woltz RL, et al. Adenylyl cyclase isoform 1 contributes to sinoatrial node automaticity via functional microdomains. *JCI insight*. 2022;7(22):e162602. <https://doi.org/10.1172/jci.insight.162602>

22. Porro A, Saponaro A, Gasparri F, Bauer D, Gross C, Pisoni M, et al. The HCN domain couples voltage gating and cAMP response in hyperpolarization-activated cyclic nucleotide-gated channels. *Elife*. 2019;8:e49672. <https://doi.org/10.7554/eLife.49672>

23. NCBI. NM_005477.3(HCN4):c.2648C>G (p.Pro883Arg) AND Sick sinus syndrome 2, autosomal dominant. NCBI - Natl Cent Biotechnol. 2024. <https://www.ncbi.nlm.nih.gov/clinvar/RCV000578029/>

24. NCBI. NM_005477.3(HCN4):c.1571G>A (p.Arg524Gln). NCBI - Natl Cent Biotechnol. 2024. <https://www.ncbi.nlm.nih.gov/clinvar/variation/941237/>

25. NCBI. rs199852438. NCBI - Natl Cent Biotechnol. 2022. <https://www.ncbi.nlm.nih.gov/snp/rs199852438>.

26. NCBI. rs148398509. NCBI - Natl Cent Biotechnol. 2022. <https://www.ncbi.nlm.nih.gov/snp/rs148398509>.

27. Heal C, Harvey A, Brown S, Rowland AG, Roland D. The association between temperature, heart rate, and respiratory rate in children aged under 16 years attending urgent and emergency care settings. *Eur J Emerg Med Off J Eur Soc Emerg Med*. 2022;29(6):413-6. <https://doi.org/10.1097/MEJ.0000000000000951>.

28. Pereira AA, Sarnak MJ. Anemia as a risk factor for cardiovascular disease. *Kidney Int Suppl*. 2003.87:S32-9. <https://doi.org/10.1046/j.1523-1755.64.s87.6.x>.

29. Brusseau V, Tauveron I, Bagheri R, Ugbolue UC, Magnon V, Bouillon-Minois J-B, et al. Effect of Hyperthyroidism Treatments on Heart Rate Variability: A Systematic Review and Meta-Analysis. *Biomedicines*. 2022;10(8):1982 <https://doi.org/10.3390/biomedicines10081982>.

FINANCING

Universitas Sebelas Maret Grant.

CONFLICT OF INTEREST

None.

AUTHORSHIP CONTRIBUTION

Conceptualization: Rasmaya Niruri, Zullies Ikawati, Agung Endro Nugroho, Habibie Arifianto.

Data curation: Rasmaya Niruri, Zullies Ikawati.

Formal analysis: Rasmaya Niruri, Zullies Ikawati.

Research: Rasmaya Niruri, Habibie Arifianto.

Methodology: Rasmaya Niruri, Zullies Ikawati, Agung Endro Nugroho, Habibie Arifianto.

Project management: Rasmaya Niruri, Zullies Ikawati.

Resources: Rasmaya Niruri, Zullies Ikawati, Habibie Arifianto.

Software: Rasmaya Niruri, Zullies Ikawati.

Supervision: Zullies Ikawati, Agung Endro Nugroho, Habibie Arifianto.

Validation: Rasmaya Niruri, Zullies Ikawati, Agung Endro Nugroho, Habibie Arifianto.

Display: Rasmaya Niruri, Zullies Ikawati.

Drafting-original draft: Rasmaya Niruri, Zullies Ikawati.

Writing- proofreading-editing: Rasmaya Niruri, Zullies Ikawati, Agung Endro Nugroho, Habibie Arifianto.